vs
Enact Holdings, Inc.（ACT）与IONIS PHARMACEUTICALS INC（IONS）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是IONIS PHARMACEUTICALS INC的1.5倍（$312.7M vs $203.3M），Enact Holdings, Inc.同比增速更快（3.6% vs -10.3%），过去两年IONIS PHARMACEUTICALS INC的营收复合增速更高（30.4% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
IONIS制药是1989年成立的生物科技企业，总部位于美国加利福尼亚州卡尔斯巴德，专注于反义疗法、RNA干扰及CRISPR疗法的研发，2015年12月前曾以Isis制药的名称运营。
ACT vs IONS — 直观对比
营收规模更大
ACT
是对方的1.5倍
$203.3M
营收增速更快
ACT
高出13.9%
-10.3%
两年增速更快
IONS
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $203.3M |
| 净利润 | — | $-229.4M |
| 毛利率 | — | 96.1% |
| 营业利润率 | 71.3% | -105.5% |
| 净利率 | — | -112.8% |
| 营收同比 | 3.6% | -10.3% |
| 净利润同比 | — | -119.8% |
| 每股收益（稀释后） | $1.23 | $-1.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTIONS
| Q4 25 | $312.7M | $203.3M | ||
| Q3 25 | $311.5M | $156.7M | ||
| Q2 25 | $304.9M | $452.0M | ||
| Q1 25 | $306.8M | $131.6M | ||
| Q4 24 | $301.8M | $226.6M | ||
| Q3 24 | $309.6M | $133.8M | ||
| Q2 24 | $298.8M | $225.3M | ||
| Q1 24 | $291.6M | $119.5M |
净利润ACTIONS
| Q4 25 | — | $-229.4M | ||
| Q3 25 | — | $-128.6M | ||
| Q2 25 | — | $123.6M | ||
| Q1 25 | — | $-146.9M | ||
| Q4 24 | — | $-104.3M | ||
| Q3 24 | — | $-140.5M | ||
| Q2 24 | — | $-66.3M | ||
| Q1 24 | — | $-142.8M |
毛利率ACTIONS
| Q4 25 | — | 96.1% | ||
| Q3 25 | — | 98.5% | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | 98.9% | ||
| Q4 24 | — | 98.3% | ||
| Q3 24 | — | 99.2% | ||
| Q2 24 | — | 98.2% | ||
| Q1 24 | — | 98.2% |
营业利润率ACTIONS
| Q4 25 | 71.3% | -105.5% | ||
| Q3 25 | 67.4% | -102.2% | ||
| Q2 25 | 70.4% | 30.9% | ||
| Q1 25 | 68.9% | -111.6% | ||
| Q4 24 | 68.9% | -48.9% | ||
| Q3 24 | 74.1% | -111.1% | ||
| Q2 24 | 78.6% | -29.3% | ||
| Q1 24 | 70.6% | -125.1% |
净利率ACTIONS
| Q4 25 | — | -112.8% | ||
| Q3 25 | — | -82.1% | ||
| Q2 25 | — | 27.3% | ||
| Q1 25 | — | -111.6% | ||
| Q4 24 | — | -46.1% | ||
| Q3 24 | — | -105.0% | ||
| Q2 24 | — | -29.4% | ||
| Q1 24 | — | -119.5% |
每股收益（稀释后）ACTIONS
| Q4 25 | $1.23 | $-1.35 | ||
| Q3 25 | $1.10 | $-0.80 | ||
| Q2 25 | $1.11 | $0.70 | ||
| Q1 25 | $1.08 | $-0.93 | ||
| Q4 24 | $1.05 | $-0.66 | ||
| Q3 24 | $1.15 | $-0.95 | ||
| Q2 24 | $1.16 | $-0.45 | ||
| Q1 24 | $1.01 | $-0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $2.7B |
| 总债务越低越好 | $744.5M | $1.8B |
| 股东权益账面价值 | $5.4B | $489.1M |
| 总资产 | $6.9B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.14× | 3.71× |
8季度趋势，按日历期对齐
现金及短期投资ACTIONS
| Q4 25 | $582.5M | $2.7B | ||
| Q3 25 | $545.6M | $2.2B | ||
| Q2 25 | $616.0M | $2.3B | ||
| Q1 25 | $639.0M | $2.1B | ||
| Q4 24 | $602.8M | $2.3B | ||
| Q3 24 | $674.9M | $2.5B | ||
| Q2 24 | $711.3M | $2.1B | ||
| Q1 24 | $624.3M | $2.2B |
总债务ACTIONS
| Q4 25 | $744.5M | $1.8B | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | $1.3B | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — | ||
| Q1 24 | $746.1M | — |
股东权益ACTIONS
| Q4 25 | $5.4B | $489.1M | ||
| Q3 25 | $5.3B | $618.0M | ||
| Q2 25 | $5.2B | $631.7M | ||
| Q1 25 | $5.1B | $475.7M | ||
| Q4 24 | $5.0B | $588.4M | ||
| Q3 24 | $5.0B | $662.5M | ||
| Q2 24 | $4.8B | $263.7M | ||
| Q1 24 | $4.7B | $296.5M |
总资产ACTIONS
| Q4 25 | $6.9B | $3.5B | ||
| Q3 25 | $6.9B | $3.0B | ||
| Q2 25 | $6.8B | $3.0B | ||
| Q1 25 | $6.7B | $2.8B | ||
| Q4 24 | $6.5B | $3.0B | ||
| Q3 24 | $6.6B | $3.1B | ||
| Q2 24 | $6.3B | $2.7B | ||
| Q1 24 | $6.3B | $2.8B |
负债/权益比ACTIONS
| Q4 25 | 0.14× | 3.71× | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | 2.13× | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $-137.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-159.0M |
| 自由现金流率自由现金流/营收 | — | -78.2% |
| 资本支出强度资本支出/营收 | — | 10.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-320.0M |
8季度趋势，按日历期对齐
经营现金流ACTIONS
| Q4 25 | $724.5M | $-137.7M | ||
| Q3 25 | $192.0M | $-131.4M | ||
| Q2 25 | $119.5M | $151.3M | ||
| Q1 25 | $226.7M | $-150.8M | ||
| Q4 24 | $686.3M | $-116.1M | ||
| Q3 24 | $188.1M | $-115.0M | ||
| Q2 24 | $144.7M | $-119.9M | ||
| Q1 24 | $187.3M | $-149.9M |
自由现金流ACTIONS
| Q4 25 | — | $-159.0M | ||
| Q3 25 | — | $-136.7M | ||
| Q2 25 | — | $139.0M | ||
| Q1 25 | — | $-163.4M | ||
| Q4 24 | — | $-141.6M | ||
| Q3 24 | — | $-124.0M | ||
| Q2 24 | — | $-126.1M | ||
| Q1 24 | — | $-154.4M |
自由现金流率ACTIONS
| Q4 25 | — | -78.2% | ||
| Q3 25 | — | -87.2% | ||
| Q2 25 | — | 30.8% | ||
| Q1 25 | — | -124.1% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -92.7% | ||
| Q2 24 | — | -56.0% | ||
| Q1 24 | — | -129.2% |
资本支出强度ACTIONS
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | — | 9.6% | ||
| Q4 24 | — | 11.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 3.8% |
现金转化率ACTIONS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.22× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
